Scientific Research & Development

GcMAF Research and Development

For over 30 years GcMAF has been researched and developed and over the past decade there have been hundreds of reports and studies advocating the role of GcMAF replacement therapy. Additionally there have been literally thousands of users of this amazing treatment provide testimony how it has helped them. If you do a search on the US Library of Medicine for GcMAF related studies you will discover papers published by more than 180 scientists in this field. Furthermore there is yet to be found any negative side-effects from using this therapy. After all GcMAF is simply a naturally-occurring protein in the human body. All we are doing with replacement therapy is helping those whose body cannot produce enough GcMAF for it to fulfill its crucial role in helping fight illness and regulating health.

For our own research and development we spent many years to ensure our products are the best on the market. Our team of scientists and technicians have many decades experience working with GcMAF and other natural health products. The special transdermal formula we developed an extremely high absorption rate. This means it is received into the body more actively than any other GcMAF cream produced. Furthermore our formula does not contain any human or animal materials like other alternatives. We extract the GcMAF from organic colostrum, sourced from certified bio-dynamic farms.however the end-product does NOT have casein – just pure GcMAF proteins. We DO NOT test on animals. This means when you choose Elixir8® you are choosing a 100% ethical and sustainable proven solution.

List of scientific & medical research done on GcMAF

This list below is directly taken from the official US Library of Medicine (http://www.ncbi.nlm.nih.gov/pubmed) searching for GcMAF related studies.

  • 1
    Hamilton G, Rath B, Klameth L, Hochmair MJ. Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. Oncoimmunology. 2015 Oct 29;5(3):e1093277. eCollection 2016 Mar. PubMed PMID: 27141354; PubMed Central PMCID: PMC4839345.
  • 2
    Delanghe JR, Speeckaert R, Speeckaert MM. Behind the scenes of vitamin D binding protein: more than vitamin D binding. Best Pract Res Clin Endocrinol Metab. 2015 Oct;29(5):773-86. doi: 10.1016/j.beem.2015.06.006. Epub 2015 Jul 2. Review. PubMed PMID: 26522461.
  • 3
    Inui T, Kubo K, Kuchiike D, Uto Y, Nishikata T, Sakamoto N, Mette M. Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports. Anticancer Res. 2015 Aug;35(8):4545-9. PubMed PMID: 26168499.
  • 4
    Uto Y, Kawai T, Sasaki T, Hamada K, Yamada H, Kuchiike D, Kubo K, Inui T, Mette M, Tokunaga K, Hayakawa A, Go A, Oosaki T. Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production. Anticancer Res. 2015 Aug;35(8):4487-92. PubMed PMID: 26168491.
  • 5
    Branca JJ, Morucci G, Malentacchi F, Gelmini S, Ruggiero M, Pacini S. Effects of oxaliplatin and oleic acid Gc-protein-derived macrophage-activating factor on murine and human microglia. J Neurosci Res. 2015 Sep;93(9):1364-77. doi: 10.1002/jnr.23588. Epub 2015 Mar 18. PubMed PMID: 25782915.
  • 6
    Morucci G, Branca JJ, Gulisano M, Ruggiero M, Paternostro F, Pacini A, Di Cesare Mannelli L, Pacini S. Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin. Anticancer Drugs. 2015 Feb;26(2):197-209. doi: 10.1097/CAD.0000000000000177. PubMed PMID: 25304987.
  • 7
    Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother. 2014 Dec;63(12):1349.
  • 8
    ‘Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)’ by Yamamoto, N., Suyama, H., Yamamoto, N. and Ushijima, N. Int J Cancer. 2014 Sep 15;135(6):1509. PubMed PMID: 25180398.
  • 9
    Inui T, Makita K, Miura H, Matsuda A, Kuchiike D, Kubo K, Mette M, Uto Y, Nishikata T, Hori H, Sakamoto N. Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy. Anticancer Res. 2014 Aug;34(8):4589-93. Erratum in: Anticancer Res. 2015 Apr;35(4):2477. PubMed PMID: 25075104.
  • 10
    Ishikawa M, Inoue T, Inui T, Kuchiike D, Kubo K, Uto Y, Nishikata T. A novel assay system for macrophage-activating factor activity using a human U937 cell line. Anticancer Res. 2014 Aug;34(8):4577-81. PubMed PMID: 25075102.
  • 11
    Ruggiero M, Ward E, Smith R, Branca JJ, Noakes D, Morucci G, Taubmann M, Thyer L, Pacini S. Oleic Acid, deglycosylated vitamin D-binding protein, nitricoxide: a molecular triad made lethal to cancer. Anticancer Res. 2014 Jul;34(7):3569-78. PubMed PMID: 24982371.
  • 12
    Siniscalco D, Bradstreet JJ, Cirillo A, Antonucci N. The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages. J Neuroinflammation. 2014 Apr 17;11:78. doi: 10.1186/1742-2094-11-78. PubMed PMID: 24739187; PubMed Central PMCID: PMC3996516.
  • 13
    Ikeda T, Kasai M, Tatsukawa E, Kamitakahara M, Shibata Y, Yokoi T, Nemoto TK, Ioku K. A bone substitute with high affinity for vitamin D-binding protein–relationship with niche of osteoclasts. J Cell Mol Med. 2014 Jan;18(1):170-80. doi: 10.1111/jcmm.12180. Epub 2013 Nov 28. PubMed PMID: 24286277; PubMed Central PMCID: PMC3916128.
  • 14
    Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S. GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients. Oncoimmunology.
  • 15
    2013 Aug 1;2(8):e25769. Epub 2013 Jul 29. PubMed PMID: 24179708; PubMed Central PMCID: PMC3812199.
  • 16
    Sayegh L, Fuleihan Gel-H, Nassar AH. Vitamin D in endometriosis: a causative or confounding factor? Metabolism. 2014 Jan;63(1):32-41. doi: 10.1016/j.metabol.2013.09.012. Epub 2013 Oct 14. Review. PubMed PMID: 24135500.